Chronic fatigue syndrome (CFS) is a complicated and poorly understood disease that causes persistent and profound fatigue. The causes of CFS are unknown.
Symptoms of CFS can come and go in cycles. People may feel better for a while, and then have a relapse. The main symptoms of CFS are:
People with CFS may also experience many other symptoms, including problems with thinking and memory, worsening of symptoms when standing or sitting up, pain, and sensitivities to external stimuli.
Treatment for CMS focuses on symptom relief. Cognitive behavioral therapy (CBT) and graded exercise therapy (GET) are two approaches that have been advocated for people with CFS and are supported by a few clinical studies. While these may work well for some patients, their appropriateness as a general indication in CFS has recently been under scrutiny. In 2017, the CDC decided to remove CBT and GET from the list of recommended therapeutic approaches for people with CFS/ME.
In 2015, the Institute of Medicine (IOM) recommended systemic exertion intolerance disease (SEID) as the new name for CFS. The IOM's goal was to have the name reflect some of the disease's core symptoms, and to hopefully remove some of the stigma that surrounds this challenging condition.
Chronic fatigue syndrome (CFS) is a serious and complex medical condition characterized by a cluster of systemic symptoms that affect physical and cognitive functioning. The hallmark symptom is persistent and profound fatigue, which often worsens after physical or mental exertion. This fatigue lasts for more than 6 months, impairs normal activities, and has no identifiable medical or psychological factors to account for it.
Fatigue is just one symptom of the condition. In addition to fatigue, people usually experience other problems such as unrefreshing sleep, difficulty with memory or concentration ("brain fog"), muscle and joint pain, and worsening of symptoms when in an upright position.
CFS is a serious condition that has a profound impact on the people who have it. Many people with CFS are forced to curtail or find new coping strategies to handle normal daily activities. About 1 in 4 people with CFS are so severely disabled that they cannot get out of bed or leave their home. Symptoms can come and go in cycles, and even when people feel better, they may experience a relapse triggered by exertion or an unknown cause.
There are a number of challenges, confusions, and controversies surrounding CFS, including defining its possible causes, exact symptoms, diagnosis, and treatment. There is even disagreement about what to call the condition.
The term "myalgic encephalomyelitis" or "ME" is sometimes added to CFS, with the disease being abbreviated as ME/CFS or CFS/ME. However, some researchers believe that ME is not appropriate because it implies brain inflammation (encephalomyelitis) and muscle pain (myalgia), which are not its main symptoms.
Many people feel that the term CFS is not accurate either because it contributes to belittling misunderstandings that undercut the serious nature of this condition. People with CFS are not lazy, neurotic, unmotivated, or suffering from the "yuppie flu." They struggle to live with a bewildering illness that is not completely understood by medical practitioners, much less the general public.
In 2015, the Institute of Medicine (IOM) proposed replacing ME/CFS with a new name: systemic exertion intolerance disease (SEID). The IOM's rationale for this name change is that SEID focuses on a core symptom of post-exertional malaise, which involves the entire body. The name also emphasizes that this condition is a "real" disease, not a psychological disorder.
However, the term SEID has not been universally embraced. Some people feel that it is still open to distortion and misrepresentation. Until SEID becomes more standardized and accepted, CFS may remain more commonly recognized as the name for this condition, and will be the term used in this report.
The exact causes of CFS are not known. Researchers think that infection, immune system problems, genetics, and the effects of stress on hormone production may play roles in different people. There may also be a genetic component. It is likely that CFS is due to a combination of factors rather than one single cause.
There is also no standard way that CFS develops. Some people have an abrupt onset of symptoms after an infectious disease or psychiatric problem. Other people experience a slowly progressive emergence of symptoms, and have no history of mental health issues.
It is not clear what sequence of events actually leads to the fatigue and other symptoms of this disorder. No primary cause has been found that explains all cases of CFS, and no blood tests or brain scans can definitively diagnose the condition.
Researchers have focused on the possibility that a virus or other type of infection may trigger CFS. Many people report having a flu-like illness or bacterial infection prior to developing CFS.
Possible viral causes include the Epstein-Barr virus (EBV) and herpesvirus type 6 (HHV-6). EBV is related to mononucleosis, which can cause severe fatigue. However, scientists have been unable to establish a causal link between EBV and CFS.
Researchers are also investigating whether CFS may be associated with the reactivation of a latent infection. Again, there is no conclusive evidence to support this theory.
A number of studies have suggested that there may be problems of regulation of the immune system in people with CFS.
Researchers are investigating whether over- or under-activation of T cells, B cells, and natural killer (NK) cells, which help regulate the immune system, may play a role in CFS. It is not yet clear whether people with CFS have the autoantibodies (antibodies that attack the body's own tissues) found in people with autoimmune disorders.
Many people with CFS have allergies or sensitivities to foods, pollen, molds, metals (such as nickel or mercury), or other substances. One theory is that allergens, like viral infections, may trigger a cascade of immune abnormalities that lead to CFS. However, most people with allergies do not have CFS.
Abnormal levels of certain chemicals in the brain system known as the hypothalamus-pituitary-adrenal (HPA) axis have been proposed as a cause of CFS. This system controls important functions, including sleep, the stress response, and depression. Some people with CFS appear to have imbalances in hormones controlled by the HPA axis, such as cortisol.
Researchers are investigating links between autonomic system dysfunction and CFS. The autonomic nervous system controls involuntary actions, including regulating blood pressure.
Some people who have CFS also have symptoms of a condition known as neurally mediated hypotension (NMH). NMH causes a dramatic drop in blood pressure when a person stands up, for even as few as 10 minutes. Its immediate effects can be light-headedness, nausea, and fainting.
A related condition experienced by some people with CFS is called postural orthostatic tachycardia syndrome (POTS). POTS causes a rapid increase in blood pressure when changing from a lying down to a standing up position.
The Institute of Medicine estimates that up to 2.5 million Americans have CFS, but millions more may have the disease and not yet been diagnosed.
CFS usually affects adults in their 30s, 40s, or 50s, but it can develop in people of all ages from children and adolescents to the elderly.
CFS is more common in women than men.
CFS sometimes occurs among members of the same family, which implies there may be a genetic link. CFS is not contagious.
There is some evidence that stress, or difficulty managing stress, may trigger CFS in people who are at risk for the disease because of genetic and other underlying factors. Stress may trigger the condition through its effects on the central nervous system, immune system, and neuroendocrine system (which is related to both nerves and hormones).
Studies have not found any consistent association between psychological, emotional, or personality factors and CFS.
A number of conditions overlap or coexist with chronic fatigue syndrome and have similar symptoms. They include fibromyalgia, irritable bowel syndrome, and sleep disorders.
People with CFS often report extreme sensitivities and physical reactions to environmental chemicals, such as those found in perfumes, cigarette smoke, or paint fumes. There is controversy and disagreement surrounding "multiple chemical sensitivities" and whether these symptoms constitute a real disorder.
The main symptoms of CFS are:
Other symptoms may include:
Additional symptoms that have been associated with CFS include abdominal bloating, urinary problems, alcohol intolerance, and sensitivity to light and loud noise.
It is very difficult to diagnose chronic fatigue syndrome. Diagnosis focuses on symptom criteria, especially unexplained and profound fatigue that has lasted at least 6 months. The symptoms of CFS tend to come on suddenly in most individuals affected by the condition.
The health care provider will take a careful personal and family medical history, and perform a thorough physical examination and psychological assessment. The provider will ask questions such as:
The provider may also ask about any changes in weight or recent illnesses. You should tell your provider about any drugs you are taking, including over-the-counter medications, and vitamin, herbal, or dietary supplements. You may be asked to keep a diary for several weeks to record your activities and symptoms.
No specific laboratory test can diagnose CFS. The following tests may be used to rule out other conditions that can cause persistent fatigue:
If any test is abnormal, it is not useful for diagnosing CFS specifically, and the provider should look for other possible causes suggested by the positive test (such as decreased thyroid function.)
Other tests for CFS may include:
Other conditions can mimic symptoms of CFS. They include:
CFS remains poorly understood and many people with the disease face challenges finding good care. It is important to recognize that there is no cure for CFS. As scientific understanding of the disease evolves, researchers hope to discover new treatments that address the disease systemically.
Current treatment focuses on relieving symptoms and helping people self-manage the condition.
You should work with your provider to develop a treatment plan that addresses your specific symptoms and concerns. It is best to begin treatment by focusing on the symptoms that cause you the most problems.
Treatment approaches by symptom may include.
Fatigue and postexertional malaise:
Emotional and Mental Health Problems:
People with CFS often experience post-exertional malaise after physical activity, which can last days to weeks. Creating an individualized plan balancing activity with appropriate periods of rest can help improve quality of life.
Try to plan a daily schedule that allows you to spread out and accomplish a certain number of activities but also allows time for adequate rest. People with CFS often find that doing too much at once can worsen symptoms and exhaustion. A strategy that allows you to plan daily rest breaks, and find a rhythm that works for your energy level, will help you feel more in control.
When you begin activity pacing (also called adaptive pacing therapy), you may find it helpful to keep a diary that tracks your activities, rest, sleep, and symptoms so that you can identify patterns and set goals.
Activity pacing should involve:
The goals of CBT include improving a person's ability to deal with stressful situations, and better manage their illness, as well as manage sleep problems and regulate activity levels.
CBT is and has been extensively used to manage CFS, however questions have been raised regarding its effectiveness. As a consequence, in 2017 the CDC has removed CBT from its list of recommended therapeutic approaches for CFS/ME.
Graded exercise therapy (GET) involves slowly increasing the duration and intensity of exercise over time. In general, people start with about 3 to 5 minutes of exercise, and then gradually increase activity over the course of several weeks.
GET does not work for all people with CFS and may worsen the condition in some. Some people experience profound fatigue after even mild or moderate exercise. Other people cannot exercise at all.
Due to concerns over its effectiveness, in 2017, the CDC has removed GET from its list of recommended treatment approaches for CFS/ME. Many specialists advise against pursuing aerobic exercise or any exercise that overly increases heart rate. Your provider may suggest that you wear a heart rate monitor while exercising. Recommended types of exercise include yoga, tai chi, and resistance and weight training.
People with CFS appear to have problems with aerobic metabolism, and must be careful not to exercise beyond their threshold. Over-exercise can worsen symptoms. For those who follow a GET approach, it is important to gradually build up to a level that is appropriate for you.
Sleep hygiene involves simple self-help measures and behavioral changes that can help improve sleep. These include:
Relaxation and stress-reduction techniques can be helpful. They include:
There is no evidence that specific foods or restrictive diets influence CFS. It is best to take a commonsense approach to a healthy diet that includes:
Discuss with your provider whether you should take a multivitamin supplement. Your provider may recommend a specific vitamin supplement if you have deficiencies in vitamin D or vitamin B12. Only use the recommended dose for vitamins: megadoses can be dangerous.
Herbs and Dietary Supplements
Many people with CFS turn to herbal and so-called "natural" remedies but there is no scientific evidence that they are effective. Be wary of supplements advertised as "immune system boosters" because they may contain unlisted steroids or pharmaceutical products. If you choose herbal remedies, stick to safe and simple ones such as peppermint or ginger tea for stomach problems and relaxation.
Be aware that the FDA does not regulate herbal remedies or dietary supplements. The amounts of the active ingredients in these remedies may not always match what is claimed on the label. Be sure to let your provider know of any herbs or supplements you are taking. Some of these products may interact with medications.
Strong, supportive relationships with family and friends are important. Attending support groups in which you share experiences with others who have CFS can be very helpful for sharing your concerns and strategies, and improving your coping abilities.
No medications are specifically approved to treat CFS. However, some medications may be useful for pain, sleep, or other symptoms. People with CFS are often very sensitive to drugs, so try to limit medication use as much as possible and use the lowest effective dose.
Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are common non-prescription pain relievers. They include aspirin, ibuprofen (Motrin, Advil), and naproxen (Aleve), and COX-2 inhibitors.
Daily use of NSAIDs can increase the risk for stomach bleeding and ulcers. Your provider may recommend that you should switch to another type of pain reliever such as acetaminophen (Tylenol), or take the NSAID along with a proton-pump inhibitor drug (PPI). PPIs include omeprazole (Prilosec) and esomeprazole (Nexium).
Talk to your provider before taking these medicines if you have kidney disease or heart disease. Your provider should be aware if you take these medicines on most days.
Nonprescription medications for sleep usually include the antihistamine diphenhydramine (Benadryl). Antihistamines can be effective when occasionally used, but in the long-term can cause problems with rebound insomnia.
Non-Benodiazepine Sedative Hypnotics
Are the preferred prescription medications for treating insomnia. They include zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta). Newer types of sedative hypnotics include ramelteon (Rozerem) and suvorexant (Belsomra).
It is important that your provider explains the risks of these drugs and the precautions you need to take. These drugs are usually prescribed for short-term use and should be taken at the lowest possible dose because they can affect next-day mental alertness and physical coordination. You should never use alcohol before taking these drugs. Long-term use of these drugs may cause problems with short-term memory.
A supplement that is a synthetic version of a hormone found in the body that is associated with regulating the circadian rhythms associated with sleep. Melatonin is a dietary supplement; therefore, it does not require FDA approval. There are no consistent standards on melatonin doses. General recommendations are to take 0.3 mg to 1 mg about 90 minutes before going to sleep. Taking higher doses may disrupt sleep and may cause daytime sleepiness, headaches, dizziness, nausea, and stomach cramps.
Other types of medications, such as tricyclic antidepressants or anticonvulsants, may be used to treat sleep problems, as well as pain.
Antidepressants known as tricyclics affect brain chemicals that are involved in managing pain. The tricyclic antidepressant amitriptyline (Elavil) is sometimes prescribed to treat pain and sleep problems associated with CFS. Other tricyclics include doxepin (Sinequan, generic), desipramine (Norpramin), nortriptyline (Pamelor), clomipramine (Anafranil), and imipramine (Tofranil).
Tricyclics for CFS pain and sleep management are given at lower doses than when used to treat depression.
Selective Serotonin-Reuptake Inhibitors (SSRIs), Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRI), and Seratonin Antagonist and Reuptake Inhibitors (SARI)
SSRIs may be helpful for people with CFS who experience significant depression. These drugs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil, Pexeva), citalopram (Celexa) and escitalopram (Lexapro).
Duloxetine (Cymbalta) and venlafaxine (Effexor) are antidepressants classified as SNRIs because they affect both neurotransmitters. SSRIs and SNRIs should not be taken with tricyclics, because the combination may cause dangerous side effects.
A tetracyclic antidepressant that works as a SARI. Trazodone is often prescribed for sleep problems.
Rituximab (Rituxan) is a biologic drug used to treat the autoimmune disease rheumatoid arthritis and certain cancers. The drug targets and blocks the activation of certain type of B cells. A small early-stage trial investigated rituximab's effectiveness in treating CFS. Results suggest that the drug may improve fatigue and other symptoms in some people with the disease. The results are preliminary and further study is needed before it can be determined if rituximab is likely to be helpful in treating CFS.
In 2016, Rintatolimod (Ampligen) an antiviral and immunomodulatory agent, was approved for the treatment of chronic fatigue syndrome in Argentina. It is also available now in Canada and Europe, but is still not approved for use in the United States. It is the only drug to receive an approval for the treatment of chronic fatigue syndrome anywhere in the world.
Bennett RM. Fibromyalgia and chronic fatigue syndrome. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 274.
Bope ET, Kellerman RD. The infectious diseases. In: Bope ET, Kellerman RD, eds. Conn's Current Therapy 2017. Philadelphia, PA: Elsevier; 2017:chap 8.
Collatz A, Johnston SC, Staines DR, Marshall-Gradisnik SM. A Systematic review of drug therapies for chronic fatigue syndrome/myalgic encephalomyelitis. Clin Ther. 2016;38(6):1263.e9-1271.e9. PMID: 27229907 www.ncbi.nlm.nih.gov/pubmed/27229907.
Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. National Academies Press, Washington, DC; 2015. PMID: 25695122 www.ncbi.nlm.nih.gov/pubmed/25695122.
Dreher M, Murray MT. Chronic Fatigue Syndrome. In: Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 4th ed. St Louis, MO: Elsevier Churchill Livingstone; 2013:chap 157.
Engleberg NC. Chronic fatigue syndrome. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Updated Edition. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 133.
Fluge Ø, Bruland O, Risa K, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358. PMID: 22039471 www.ncbi.nlm.nih.gov/pubmed/22039471.
International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. ME/CFS: A primer for clinical practitioners. www.iacfsme.org/portals/0/pdf/primerfinal3.pdf. Accessed July 21, 2017.
Jason LA, Brown A, Evans M, Sunnquist M, Newton JL. Contrasting chronic fatigue syndrome versus myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue. 2013;1(3):168-186. PMID: 23914329 www.ncbi.nlm.nih.gov/pubmed/23914329.
Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2017;4:CD003200. PMID: 28444695 www.ncbi.nlm.nih.gov/pubmed/28444695.
Santhouse A, Hotopf M, David AS. Chronic fatigue syndrome. BMJ. 2010;340:c738. PMID: 20150199 www.ncbi.nlm.nih.gov/pubmed/20150199.
Smith MEB, Nelson HD, Haney E, et al. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Evidence Report/Technology Assessment No. 219. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 15-E001-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. www.ncbi.nlm.nih.gov/books/NBK293931. Accessed March 17, 2015.
White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive pacing therapy, cognitive behavior therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377(9768):823-836. PMID: 21334061 www.ncbi.nlm.nih.gov/pubmed/21334061.
Reviewed By: Robert Hurd, MD, Professor of Endocrinology and Health Care Ethics, Xavier University, Cincinnati, OH. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.